New Delhi, March 23: Institute of Life Sciences, Bhubaneswar has transferred a technology for production of curcumin sponge for wound healing. During last few years, ILS has been working on developing a product and has demonstrated the efficacy of curcumin encapsulated in chitosan and alginate polymers for cure of various inflammatory and oxidative stress related disease including wound healing.

Wound healing is a complex physiological response to injury. In severe pathologic conditions this cascade healing process is lost and the wounds are locked into a state of chronic inflammation. Wound treatment and its therapeutic impediments represent an economically challenging burden on healthcare worldwide.

In India, around 4.5 per thousand people are affected by chronic wounds and this almost doubles to 10.5 per thousand for acute wounds. Plant-based products have multi-targeting potential, and in addition are inexpensive and safe compared to synthetic agents. Turmeric biologically called Curcuma longa L is an important cash crop grown by tribal farmers of India particularly Odisha.

ILS had already entered in MOA (memorandum of association) with NRDC (An enterprise of DSIR, Ministry of Science and Technology) in 2015 for commercialisation of this product. Based on extensive discussions, NRDC has identified Golap Pharmaceuticals, Jaipur for mass scale production and commercialization of curcumin sponge.

The technology has been developed by Dr. Sanjeeb Sahoo, Scientist at ILS and his group. The product was launched in presence Dr. Manju Sharma, Former Secretary, Dept of Biotechnology and Dr. Ajay Parida, Director, ILS. Dr H. Purushotham, Chairman & Managing Director from NRDC and Mr Srayance Jain, Director from Gulap Pharmaceuticals signed the agreement for commercialization.

Contact Person & Contact Details:
Dr Mamoni Dash (Communication officer); Dr Sanjeeb K Sahoo (Scientist E)